Roche - AVAglio Study Positive: PFS Endpoint Met in Glioblastoma
Roche reported that Avastin plus radiation and temozolomide chemotherapy significantly improved progression free survival as first-line therapy in glioblastoma. We expect a successful approval and the indication should add $750m in sales for Avastin. The final overall survival data is expected in 2013. In the Phase 2 trial Avastin in combination with standard of care has demonstrated an OS of 19.6 m in the first line setting, while the standard of Care –Temodar with radiotherapy was associated with an OS of 14.6 m in the first line setting. On the basis of PhII data, Avastin was granted accelerated approval as monotherapy in recurrent Glioblastoma in the US in 2009.
More Publications
Lemtrada: Co-primary Endpoints Met in CARE MS II: Ready for filing
US$ 90.00
November 2011
4 pages
NOVARTIS - PASPORT Head to Head Study positive: Sandostatin LAR Replacement Ready in active acromegaly
US$ 90.00
May 2012
2 pages
